These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
107 related items for PubMed ID: 318766
1. Chelation therapy for the treatment of thalassemia. Graziano JH, Cerami A. Semin Hematol; 1977 Jan; 14(1):127-34. PubMed ID: 318766 [No Abstract] [Full Text] [Related]
2. Iron excretion in thalassemia after the administration of chelating agents. Markum AH, Iskandar W, Keng KL, Odang O. Paediatr Indones; 1969 Jan; 9(3):89-98. PubMed ID: 4981722 [No Abstract] [Full Text] [Related]
3. Editorial: Thalassemia major: a problem of iron overload. Stockman JA, Oski FA. Ann Intern Med; 1974 Aug; 81(2):262-3. PubMed ID: 4846109 [No Abstract] [Full Text] [Related]
4. Clinical management of thalassemia. The status of new iron chelators. Cerami A, Grady RW, Peterson CM, Bhargava KK. Ann N Y Acad Sci; 1980 Aug; 344():425-35. PubMed ID: 6446872 [No Abstract] [Full Text] [Related]
5. Clinical usefulness of iron chelating agents. Waxman HS, Brown EB. Prog Hematol; 1969 Aug; 6():338-73. PubMed ID: 4976246 [No Abstract] [Full Text] [Related]
6. Deferoxamine and diethylenetriaminepentaacetic acid (DTPA) in thalassemia. McDonald R. J Pediatr; 1966 Oct; 69(4):563-71. PubMed ID: 5921331 [No Abstract] [Full Text] [Related]
7. Combined use of oral chelators and desferrioxamine in thalassemia. Piga A, Roggero S, Marletto F, Sacchetti L, Longo F. Hematology; 2005 Oct; 10 Suppl 1():89-91. PubMed ID: 16188646 [No Abstract] [Full Text] [Related]
8. Long-term chelation therapy in thalassaemia major: effect on liver iron concentration, liver histology, and clinical progress. Barry M, Flynn DM, Letsky EA, Risdon RA. Br Med J; 1974 Apr 06; 2(5909):16-20. PubMed ID: 4821036 [Abstract] [Full Text] [Related]
10. Chelation therapy for iron overload. Nutr Rev; 1980 May 06; 38(5):185-7. PubMed ID: 7207885 [No Abstract] [Full Text] [Related]
11. Chelation studies with 2,3-dihydroxybenzoic acid in patients with beta-thalassaemia major. Peterson CM, Graziano JH, Grady RW, Jones RL, Vlassara HV, Canale VC, Miller DR, Cerami A. Br J Haematol; 1976 Aug 06; 33(4):477-85. PubMed ID: 1009020 [Abstract] [Full Text] [Related]
12. Iron metabolism and chelation therapy in hemosiderosis. Graziano JH. Curr Top Hematol; 1978 Aug 06; 1():127-50. PubMed ID: 400529 [No Abstract] [Full Text] [Related]
13. [Iron-chelating treatment]. Vullo C, Di Palma A, De Sanctis V, Borgatti L, Atti G. Haematologica; 1989 Oct 06; 74(5 Suppl):241-51. PubMed ID: 2512211 [No Abstract] [Full Text] [Related]
14. Glucose tolerance and chelation therapy in patients with thalassaemia major. Capra L, Atti G, De Sanctis V, Candini G. Haematologica; 1983 Oct 06; 68(1):63-8. PubMed ID: 6404709 [No Abstract] [Full Text] [Related]
18. Pathogenesis and management of iron overload in thalassemia. Hershko C. Haematologica; 1975 Jun 06; 60(2):241-8. PubMed ID: 808456 [No Abstract] [Full Text] [Related]
19. [Observations on the internal decontamination of radioelements]. Brenot A, Chiadot P, Rinaldi R. Ann Biol Clin (Paris); 1966 Jun 06; 24(10):1223-30. PubMed ID: 5983186 [No Abstract] [Full Text] [Related]
20. [Hypertransfusion, chelating and immunocorrective therapy in beta-thalassemia major]. Zeĭnalova AA, Ragimov AA, Dashkova NG, Mamedova FR, Kurbanova SA. Pediatriia; 1987 Jun 06; (2):55-60. PubMed ID: 3575062 [No Abstract] [Full Text] [Related] Page: [Next] [New Search]